Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Launched by UNIVERSITY OF CINCINNATI · May 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat large tumors in cancer patients using a method called lattice radiation therapy (LRT). The goal is to find out if LRT can be more effective than the standard radiation therapy currently used. The trial is open to adults aged 18 and older who have solid tumors that can be treated with radiation and have a good chance of living for at least three more months. Participants need to have measurable tumors and must be willing to follow guidelines regarding pregnancy prevention during the study.

If you join this trial, you will receive lattice radiation therapy, which is designed to target your tumor more precisely. The researchers will monitor your health and how well the treatment works. It's important to note that if you are currently receiving certain types of chemotherapy or have specific health conditions, you may not be eligible to participate. Overall, the study aims to see if this new treatment can improve outcomes for patients with large tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Solid tumor malignancy with a clinical indication for radiation
• • Patients must have measurable disease
• • Target lesion(s) which are amenable to lattice therapy plan
• • When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy
• • Age ≥18 years.
• • ECOG Performance status ≤2
• • Life expectancy greater than 3 months
• • Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.
• • Ability to understand and the willingness to sign a written informed consent document
• Exclusion Criteria:
• • Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.
• • Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.
• • Patients with a history of conditions which predispose them to increased radiation toxicity
• • Patients with known contraindications to radiation therapy
• • Patients with uncontrolled intercurrent illness
• • Pregnant women